Stock TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE

Equities

IL0006290147

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 15.92B 59.17B 21.76B Sales 2025 * 16.49B 61.29B 22.54B Capitalization 18.41B 68.41B 25.16B
Net income 2024 * 820M 3.05B 1.12B Net income 2025 * 1.39B 5.16B 1.9B EV / Sales 2024 * 2.09 x
Net Debt 2024 * 14.93B 55.48B 20.4B Net Debt 2025 * 12.41B 46.12B 16.96B EV / Sales 2025 * 1.87 x
P/E ratio 2024 *
17.3 x
P/E ratio 2025 *
12 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.71%
More Fundamentals * Assessed data

Chart Teva Pharmaceutical Industries Limited

Dynamic Chart

Latest news about Teva Pharmaceutical Industries Limited

Sector Update: Health Care Stocks Slipping Wednesday Afternoon MT
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday MT
Sector Update: Health Care MT
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 Revenue $3.82B MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 EPS $0.48 MT
Transcript : Teva Pharmaceutical Industries Limited, Q1 2024 Earnings Call, May 08, 2024
Teva Pharm Q1 profit falls short of estimates, revenue gains RE
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Teva Pharmaceutical Industries Limited Reports Impairment of Long-Lived Assets for the Three Months Ended March 31, 2024 CI
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024 CI
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
More news

Latest transcript on Teva Pharmaceutical Industries Limited

Logo Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, Q1 2024 Earnings Call, May 08, 2024
More transcripts

Analyst Recommendations on Teva Pharmaceutical Industries Limited

JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11 MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12 MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating MT
More recommendations

Press releases Teva Pharmaceutical Industries Limited

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia AQ
Teva Pharmaceutical Industries : Immediate Report PU
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook BU
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets AQ
Teva to Present at the 2024 Bank of America Healthcare Conference BU
More press releases

News in other languages on Teva Pharmaceutical Industries Limited

En Direct des Marchés : Sabadell, TotalEnergies, Airbnb, ARM, Medincell, Nexi...
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor
FDA rechaza aprobación de inyección de Viatris para la esclerosis múltiple
Alcoa : Berkshire Hathaway, Teva... les valeurs à suivre aujourd'hui à Wall Street -
Teva Pharmaceutical Industries : attendu en hausse après l'approbation du Simlandi par la FDA
More news

Managers and Directors - Teva Pharmaceutical Industries Limited

Managers TitleAgeSince
Richard Francis CEO
 Chief Executive Officer 55 22-12-31
Eli Kalif DFI
 Director of Finance/CFO 51 19-12-21
Eric Hughes CTO
 Chief Tech/Sci/R&D Officer - 22-07-31
Members of the board TitleAgeSince
Gerald Lieberman BRD
 Director/Board Member 77 15-08-31
Janet Vergis BRD
 Director/Board Member 59 20-06-08
Sol Barer CHM
 Chairman 76 14-12-31
More insiders

Company Profile

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
Pharmaceuticals
Calendar
2024-05-14 - BofA Securities Health Care Conference
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW